| Analysis | Metabolite Name | Measured Value | Units | Group |
|---|---|---|---|---|
| Reversed phase POSITIVE ION MODE | N-acetylaspartate (NAA) | 0.3466 | Peak area | Obese non neuropathy |
| Reversed phase POSITIVE ION MODE | N-acetylaspartate (NAA) | 0.3786 | Peak area | Obese non neuropathy |
| Reversed phase POSITIVE ION MODE | N-acetylaspartate (NAA) | 0.4087 | Peak area | Obese non neuropathy |
| Reversed phase POSITIVE ION MODE | N-acetylaspartate (NAA) | 0.5154 | Peak area | Lean |
| Reversed phase POSITIVE ION MODE | N-acetylaspartate (NAA) | 0.5645 | Peak area | Obese non neuropathy |
| Reversed phase POSITIVE ION MODE | N-acetylaspartate (NAA) | 0.5860 | Peak area | Lean |
| Reversed phase POSITIVE ION MODE | N-acetylaspartate (NAA) | 0.6004 | Peak area | Obese non neuropathy |
| Reversed phase POSITIVE ION MODE | N-acetylaspartate (NAA) | 0.6230 | Peak area | Lean |
| Reversed phase POSITIVE ION MODE | N-acetylaspartate (NAA) | 0.6407 | Peak area | Obese non neuropathy |
| Reversed phase POSITIVE ION MODE | N-acetylaspartate (NAA) | 0.6422 | Peak area | Lean |
| Reversed phase POSITIVE ION MODE | N-acetylaspartate (NAA) | 0.6656 | Peak area | Obese neuropathy |
| Reversed phase POSITIVE ION MODE | N-acetylaspartate (NAA) | 0.6660 | Peak area | Obese neuropathy |
| Reversed phase POSITIVE ION MODE | N-acetylaspartate (NAA) | 0.6662 | Peak area | Obese non neuropathy |
| Reversed phase POSITIVE ION MODE | N-acetylaspartate (NAA) | 0.6671 | Peak area | Lean |
| Reversed phase POSITIVE ION MODE | N-acetylaspartate (NAA) | 0.6717 | Peak area | Lean |
| Reversed phase POSITIVE ION MODE | N-acetylaspartate (NAA) | 0.6785 | Peak area | Lean |
| Reversed phase POSITIVE ION MODE | N-acetylaspartate (NAA) | 0.6921 | Peak area | Lean |
| Reversed phase POSITIVE ION MODE | N-acetylaspartate (NAA) | 0.6947 | Peak area | Obese non neuropathy |
| Reversed phase POSITIVE ION MODE | N-acetylaspartate (NAA) | 0.6966 | Peak area | Obese non neuropathy |
| Reversed phase POSITIVE ION MODE | N-acetylaspartate (NAA) | 0.7000 | Peak area | Obese neuropathy |
| Reversed phase POSITIVE ION MODE | N-acetylaspartate (NAA) | 0.7034 | Peak area | Obese non neuropathy |
| Reversed phase POSITIVE ION MODE | N-acetylaspartate (NAA) | 0.7254 | Peak area | Obese non neuropathy |
| Reversed phase POSITIVE ION MODE | N-acetylaspartate (NAA) | 0.7262 | Peak area | Obese non neuropathy |
| Reversed phase POSITIVE ION MODE | N-acetylaspartate (NAA) | 0.7292 | Peak area | Lean |
| Reversed phase POSITIVE ION MODE | N-acetylaspartate (NAA) | 0.7405 | Peak area | Lean |
| Reversed phase POSITIVE ION MODE | N-acetylaspartate (NAA) | 0.7840 | Peak area | Obese neuropathy |
| Reversed phase POSITIVE ION MODE | N-acetylaspartate (NAA) | 0.7935 | Peak area | Obese neuropathy |
| Reversed phase POSITIVE ION MODE | N-acetylaspartate (NAA) | 0.7941 | Peak area | Obese neuropathy |
| Reversed phase POSITIVE ION MODE | N-acetylaspartate (NAA) | 0.8016 | Peak area | Obese non neuropathy |
| Reversed phase POSITIVE ION MODE | N-acetylaspartate (NAA) | 0.8094 | Peak area | Obese neuropathy |
| Reversed phase POSITIVE ION MODE | N-acetylaspartate (NAA) | 0.8169 | Peak area | Obese neuropathy |
| Reversed phase POSITIVE ION MODE | N-acetylaspartate (NAA) | 0.8209 | Peak area | Obese neuropathy |
| Reversed phase POSITIVE ION MODE | N-acetylaspartate (NAA) | 0.8279 | Peak area | Lean |
| Reversed phase POSITIVE ION MODE | N-acetylaspartate (NAA) | 0.8287 | Peak area | Lean |
| Reversed phase POSITIVE ION MODE | N-acetylaspartate (NAA) | 0.8374 | Peak area | Obese non neuropathy |
| Reversed phase POSITIVE ION MODE | N-acetylaspartate (NAA) | 0.8399 | Peak area | Obese neuropathy |
| Reversed phase POSITIVE ION MODE | N-acetylaspartate (NAA) | 0.8427 | Peak area | Obese non neuropathy |
| Reversed phase POSITIVE ION MODE | N-acetylaspartate (NAA) | 0.8499 | Peak area | Obese non neuropathy |
| Reversed phase POSITIVE ION MODE | N-acetylaspartate (NAA) | 0.8588 | Peak area | Obese non neuropathy |
| Reversed phase POSITIVE ION MODE | N-acetylaspartate (NAA) | 0.8613 | Peak area | Obese non neuropathy |
| Reversed phase POSITIVE ION MODE | N-acetylaspartate (NAA) | 0.8616 | Peak area | Lean |
| Reversed phase POSITIVE ION MODE | N-acetylaspartate (NAA) | 0.8618 | Peak area | Obese non neuropathy |
| Reversed phase POSITIVE ION MODE | N-acetylaspartate (NAA) | 0.8641 | Peak area | Obese neuropathy |
| Reversed phase POSITIVE ION MODE | N-acetylaspartate (NAA) | 0.8650 | Peak area | Lean |
| Reversed phase POSITIVE ION MODE | N-acetylaspartate (NAA) | 0.8650 | Peak area | Obese neuropathy |
| Reversed phase POSITIVE ION MODE | N-acetylaspartate (NAA) | 0.8913 | Peak area | Obese neuropathy |
| Reversed phase POSITIVE ION MODE | N-acetylaspartate (NAA) | 0.9009 | Peak area | Obese non neuropathy |
| Reversed phase POSITIVE ION MODE | N-acetylaspartate (NAA) | 0.9104 | Peak area | Obese non neuropathy |
| Reversed phase POSITIVE ION MODE | N-acetylaspartate (NAA) | 0.9124 | Peak area | Lean |
| Reversed phase POSITIVE ION MODE | N-acetylaspartate (NAA) | 0.9142 | Peak area | Obese neuropathy |
| Reversed phase POSITIVE ION MODE | N-acetylaspartate (NAA) | 0.9155 | Peak area | Obese non neuropathy |
| Reversed phase POSITIVE ION MODE | N-acetylaspartate (NAA) | 0.9172 | Peak area | Lean |
| Reversed phase POSITIVE ION MODE | N-acetylaspartate (NAA) | 0.9176 | Peak area | Lean |
| Reversed phase POSITIVE ION MODE | N-acetylaspartate (NAA) | 0.9191 | Peak area | Obese non neuropathy |
| Reversed phase POSITIVE ION MODE | N-acetylaspartate (NAA) | 0.9254 | Peak area | Obese non neuropathy |
| Reversed phase POSITIVE ION MODE | N-acetylaspartate (NAA) | 0.9399 | Peak area | Lean |
| Reversed phase POSITIVE ION MODE | N-acetylaspartate (NAA) | 0.9482 | Peak area | Obese non neuropathy |
| Reversed phase POSITIVE ION MODE | N-acetylaspartate (NAA) | 0.9566 | Peak area | Lean |
| Reversed phase POSITIVE ION MODE | N-acetylaspartate (NAA) | 0.9647 | Peak area | Lean |
| Reversed phase POSITIVE ION MODE | N-acetylaspartate (NAA) | 0.9653 | Peak area | Obese non neuropathy |
| Reversed phase POSITIVE ION MODE | N-acetylaspartate (NAA) | 0.9710 | Peak area | Obese non neuropathy |
| Reversed phase POSITIVE ION MODE | N-acetylaspartate (NAA) | 0.9759 | Peak area | Obese non neuropathy |
| Reversed phase POSITIVE ION MODE | N-acetylaspartate (NAA) | 0.9851 | Peak area | Lean |
| Reversed phase POSITIVE ION MODE | N-acetylaspartate (NAA) | 0.9934 | Peak area | Lean |
| Reversed phase POSITIVE ION MODE | N-acetylaspartate (NAA) | 0.9978 | Peak area | Obese neuropathy |
| Reversed phase POSITIVE ION MODE | N-acetylaspartate (NAA) | 1.0000 | Peak area | Obese neuropathy |
| Reversed phase POSITIVE ION MODE | N-acetylaspartate (NAA) | 1.0045 | Peak area | Lean |
| Reversed phase POSITIVE ION MODE | N-acetylaspartate (NAA) | 1.0078 | Peak area | Obese neuropathy |
| Reversed phase POSITIVE ION MODE | N-acetylaspartate (NAA) | 1.0097 | Peak area | Lean |
| Reversed phase POSITIVE ION MODE | N-acetylaspartate (NAA) | 1.0147 | Peak area | Obese neuropathy |
| Reversed phase POSITIVE ION MODE | N-acetylaspartate (NAA) | 1.0159 | Peak area | Obese neuropathy |
| Reversed phase POSITIVE ION MODE | N-acetylaspartate (NAA) | 1.0176 | Peak area | Lean |
| Reversed phase POSITIVE ION MODE | N-acetylaspartate (NAA) | 1.0250 | Peak area | Obese neuropathy |
| Reversed phase POSITIVE ION MODE | N-acetylaspartate (NAA) | 1.0324 | Peak area | Obese neuropathy |
| Reversed phase POSITIVE ION MODE | N-acetylaspartate (NAA) | 1.0377 | Peak area | Obese neuropathy |
| Reversed phase POSITIVE ION MODE | N-acetylaspartate (NAA) | 1.0564 | Peak area | Obese neuropathy |
| Reversed phase POSITIVE ION MODE | N-acetylaspartate (NAA) | 1.0858 | Peak area | Obese non neuropathy |
| Reversed phase POSITIVE ION MODE | N-acetylaspartate (NAA) | 1.0881 | Peak area | Obese non neuropathy |
| Reversed phase POSITIVE ION MODE | N-acetylaspartate (NAA) | 1.0973 | Peak area | Lean |
| Reversed phase POSITIVE ION MODE | N-acetylaspartate (NAA) | 1.1051 | Peak area | Obese neuropathy |
| Reversed phase POSITIVE ION MODE | N-acetylaspartate (NAA) | 1.1330 | Peak area | Obese non neuropathy |
| Reversed phase POSITIVE ION MODE | N-acetylaspartate (NAA) | 1.1348 | Peak area | Obese non neuropathy |
| Reversed phase POSITIVE ION MODE | N-acetylaspartate (NAA) | 1.1449 | Peak area | Obese neuropathy |
| Reversed phase POSITIVE ION MODE | N-acetylaspartate (NAA) | 1.1608 | Peak area | Obese non neuropathy |
| Reversed phase POSITIVE ION MODE | N-acetylaspartate (NAA) | 1.1676 | Peak area | Obese neuropathy |
| Reversed phase POSITIVE ION MODE | N-acetylaspartate (NAA) | 1.1807 | Peak area | Obese neuropathy |
| Reversed phase POSITIVE ION MODE | N-acetylaspartate (NAA) | 1.2037 | Peak area | Obese neuropathy |
| Reversed phase POSITIVE ION MODE | N-acetylaspartate (NAA) | 1.2042 | Peak area | Obese non neuropathy |
| Reversed phase POSITIVE ION MODE | N-acetylaspartate (NAA) | 1.2056 | Peak area | Obese neuropathy |
| Reversed phase POSITIVE ION MODE | N-acetylaspartate (NAA) | 1.2088 | Peak area | Obese neuropathy |
| Reversed phase POSITIVE ION MODE | N-acetylaspartate (NAA) | 1.2099 | Peak area | Obese neuropathy |
| Reversed phase POSITIVE ION MODE | N-acetylaspartate (NAA) | 1.2207 | Peak area | Obese non neuropathy |
| Reversed phase POSITIVE ION MODE | N-acetylaspartate (NAA) | 1.2300 | Peak area | Obese non neuropathy |
| Reversed phase POSITIVE ION MODE | N-acetylaspartate (NAA) | 1.2343 | Peak area | Obese neuropathy |
| Reversed phase POSITIVE ION MODE | N-acetylaspartate (NAA) | 1.2373 | Peak area | Lean |
| Reversed phase POSITIVE ION MODE | N-acetylaspartate (NAA) | 1.2397 | Peak area | Lean |
| Reversed phase POSITIVE ION MODE | N-acetylaspartate (NAA) | 1.2523 | Peak area | Lean |
| Reversed phase POSITIVE ION MODE | N-acetylaspartate (NAA) | 1.2891 | Peak area | Obese neuropathy |
| Reversed phase POSITIVE ION MODE | N-acetylaspartate (NAA) | 1.2964 | Peak area | Obese neuropathy |
| Reversed phase POSITIVE ION MODE | N-acetylaspartate (NAA) | 1.2966 | Peak area | Lean |
| Reversed phase POSITIVE ION MODE | N-acetylaspartate (NAA) | 1.2980 | Peak area | Obese neuropathy |
| Reversed phase POSITIVE ION MODE | N-acetylaspartate (NAA) | 1.3033 | Peak area | Obese neuropathy |
| Reversed phase POSITIVE ION MODE | N-acetylaspartate (NAA) | 1.3109 | Peak area | Lean |
| Reversed phase POSITIVE ION MODE | N-acetylaspartate (NAA) | 1.3140 | Peak area | Lean |
| Reversed phase POSITIVE ION MODE | N-acetylaspartate (NAA) | 1.3413 | Peak area | Lean |
| Reversed phase POSITIVE ION MODE | N-acetylaspartate (NAA) | 1.3438 | Peak area | Lean |
| Reversed phase POSITIVE ION MODE | N-acetylaspartate (NAA) | 1.3461 | Peak area | Lean |
| Reversed phase POSITIVE ION MODE | N-acetylaspartate (NAA) | 1.3682 | Peak area | Obese neuropathy |
| Reversed phase POSITIVE ION MODE | N-acetylaspartate (NAA) | 1.3751 | Peak area | Obese non neuropathy |
| Reversed phase POSITIVE ION MODE | N-acetylaspartate (NAA) | 1.3824 | Peak area | Lean |
| Reversed phase POSITIVE ION MODE | N-acetylaspartate (NAA) | 1.3875 | Peak area | Lean |
| Reversed phase POSITIVE ION MODE | N-acetylaspartate (NAA) | 1.4018 | Peak area | Obese non neuropathy |
| Reversed phase POSITIVE ION MODE | N-acetylaspartate (NAA) | 1.4332 | Peak area | Obese neuropathy |
| Reversed phase POSITIVE ION MODE | N-acetylaspartate (NAA) | 1.5121 | Peak area | Lean |
| Reversed phase POSITIVE ION MODE | N-acetylaspartate (NAA) | 1.5270 | Peak area | Lean |
| Reversed phase POSITIVE ION MODE | N-acetylaspartate (NAA) | 1.5286 | Peak area | Lean |
| Reversed phase POSITIVE ION MODE | N-acetylaspartate (NAA) | 1.5310 | Peak area | Obese neuropathy |
| Reversed phase POSITIVE ION MODE | N-acetylaspartate (NAA) | 1.5328 | Peak area | Obese neuropathy |
| Reversed phase POSITIVE ION MODE | N-acetylaspartate (NAA) | 1.5839 | Peak area | Obese non neuropathy |
| Reversed phase POSITIVE ION MODE | N-acetylaspartate (NAA) | 1.5863 | Peak area | Obese non neuropathy |
| Reversed phase POSITIVE ION MODE | N-acetylaspartate (NAA) | 1.6146 | Peak area | Obese non neuropathy |
| Reversed phase POSITIVE ION MODE | N-acetylaspartate (NAA) | 1.6705 | Peak area | Obese neuropathy |
| Reversed phase POSITIVE ION MODE | N-acetylaspartate (NAA) | 1.6768 | Peak area | Obese neuropathy |
| Reversed phase POSITIVE ION MODE | N-acetylaspartate (NAA) | 1.7323 | Peak area | Obese neuropathy |
| Reversed phase POSITIVE ION MODE | N-acetylaspartate (NAA) | 1.7853 | Peak area | Lean |
| Reversed phase POSITIVE ION MODE | N-acetylaspartate (NAA) | 1.9447 | Peak area | Obese neuropathy |
| Reversed phase POSITIVE ION MODE | N-acetylaspartate (NAA) | 2.1179 | Peak area | Obese non neuropathy |
| Reversed phase POSITIVE ION MODE | N-acetylaspartate (NAA) | 2.2443 | Peak area | Obese non neuropathy |
| Reversed phase POSITIVE ION MODE | N-acetylaspartate (NAA) | 2.3638 | Peak area | Obese non neuropathy |
| Reversed phase POSITIVE ION MODE | N-acetylaspartate (NAA) | 3.1278 | Peak area | Lean |
| Reversed phase POSITIVE ION MODE | N-acetylaspartate (NAA) | 3.4258 | Peak area | Lean |
- UCSD Metabolomics Workbench, a resource sponsored by the Common Fund of the National Institutes of Health
|